U.S. Food and Drug Administration • Center for Drug Evaluation and Research
Antimicrobial Resistance
FDA, in cooperation with other Public Health Service Agencies, has embarked on several major initiatives to address what is considered to be a major threat to the Public Health in the new millennium: the emergence of drug-resistant bacteria.
This page is designed to permit ready access to FDA and CDER activities, initiatives, policies, and information regarding antimicrobial resistance (also known as drug resistance or antibiotic resistance), both for health professionals and consumers. General and technical information on antimicrobial resistance is also available at the Centers for Disease Control (CDC) Antimicrobial Resistance Web Site. This CDC web site has an extensive catalog of information about antimicrobial resistance, including fact sheets about specific pathogens and published clinical guidelines.
Since 1996, FDA has actively addressed the issue of antimicrobial resistance through several major initiatives. As an agency composed of several separate centers, including the Center for Veterinary Medicine (CVM), Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health, and the Center for Food Safety and Nutrition, FDA has addressed antimicrobial resistance through a variety of initiatives. These initiatives include an agency-wide cooperative effort, the FDA Task Force on Antimicrobial Resistance, specific activities within each center, and participation on the Public Health Service Task Force on Antimicrobial Resistance (PHS Draft Public Health Action Plan to Combat Antimicrobial Resistance: Action Plan and Federal Register Notices).
CDER, the Center for Drug Evaluation and Research, is home to (among others) the Divisions of Anti-Infective Drug Products, Special Pathogen and Immunologic Drug Products, Antiviral Drug Products (all within the Office of Drug Evaluation IV), the Division of Over-the-Counter Drug Products (within the Office of Drug Evaluation V), and the Office of Generic Drugs. These offices all have involvement in FDA's efforts to address antimicrobial resistance. (CDER organizational map)
Your information is protected by Thawte Digital Certificate Services. Please CLICK on the Icon below
to see the actual date
[Sun] [References] [Glossary of Terms] [Web Site Review] [Order Rosacea-Ltd III]
This page was last updated on May 8, 2008.
Copyright © 1998-2007 Bass & Boney Pharmaceuticals, Inc.